ZHX2

Across TCGA pan-cancer cohorts, ZHX2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZHX2 data layer compared with 21 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ZHX2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ZHX2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, CCRCC, and UCEC are the cancer types where ZHX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.963	0.765	.002	34	view →
CCRCC	OS	Median	All	0.697	0.919	.030	7	view →
UCEC	OS	Tertile	III,IV	0.488	1.000	.042	4	view →
PDAC	OS	Median	IV	0.911	0.540	.049	3	view →
LUAD	OS	Quartile	II,III,IV	0.848	0.344	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZHX2–LSCC (OS)

Open the LSCC breakdown →